MX2022015579A - 2-oxo-oxazolidin-5-carboxamidas como inhibidores de nav1.8. - Google Patents

2-oxo-oxazolidin-5-carboxamidas como inhibidores de nav1.8.

Info

Publication number
MX2022015579A
MX2022015579A MX2022015579A MX2022015579A MX2022015579A MX 2022015579 A MX2022015579 A MX 2022015579A MX 2022015579 A MX2022015579 A MX 2022015579A MX 2022015579 A MX2022015579 A MX 2022015579A MX 2022015579 A MX2022015579 A MX 2022015579A
Authority
MX
Mexico
Prior art keywords
sub
disorders
inhibitors
carboxamides
oxazolidine
Prior art date
Application number
MX2022015579A
Other languages
English (en)
Inventor
Hong Liu
Jian Liu
Ashok Arasappan
Jason M Cox
Ian M Bell
Christopher James Bungard
Christopher S Burgey
Deodial Guy Guiadeen
Mark E Layton
James J Perkins
Shawn J Stachel
Zhe Wu
Iii Michael J Kelly
James T Olsen
Jeffrey W Schubert
Akshay A Shah
Michael D Vanheyst
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2022015579A publication Critical patent/MX2022015579A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos novedosos de la fórmula estructural (I), y las sales farmacéuticamente aceptables de los mismos, son inhibidores de actividad de canales de Nav1.8 y pueden ser útiles en el tratamiento, prevención, manejo, mejoramiento, control y supresión de enfermedades mediadas por actividad de canales de Nav1.8. Los compuestos de la presente invención pueden ser útiles en el tratamiento, prevención o manejo de trastornos de dolor, trastornos de tos, trastornos de comezón aguda y trastornos de comezón crónica. (ver Fórmula).
MX2022015579A 2020-06-17 2021-06-14 2-oxo-oxazolidin-5-carboxamidas como inhibidores de nav1.8. MX2022015579A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040463P 2020-06-17 2020-06-17
PCT/US2021/037157 WO2021257418A1 (en) 2020-06-17 2021-06-14 2-oxo-oxazolidine-5-carboxamides as nav1.8 inhibitors

Publications (1)

Publication Number Publication Date
MX2022015579A true MX2022015579A (es) 2023-01-24

Family

ID=79268310

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015579A MX2022015579A (es) 2020-06-17 2021-06-14 2-oxo-oxazolidin-5-carboxamidas como inhibidores de nav1.8.

Country Status (10)

Country Link
US (1) US20230227441A1 (es)
EP (1) EP4167994A1 (es)
JP (1) JP2023530319A (es)
KR (1) KR20230026404A (es)
CN (1) CN116056697A (es)
AU (1) AU2021292061A1 (es)
BR (1) BR112022024450A2 (es)
CA (1) CA3182610A1 (es)
MX (1) MX2022015579A (es)
WO (1) WO2021257418A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117813302A (zh) 2021-06-04 2024-04-02 沃泰克斯药物股份有限公司 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂
EP4347031A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
AU2022285758A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
WO2022256708A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
JP2024520643A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン
EP4347584A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain

Also Published As

Publication number Publication date
KR20230026404A (ko) 2023-02-24
BR112022024450A2 (pt) 2022-12-27
JP2023530319A (ja) 2023-07-14
CA3182610A1 (en) 2021-12-23
US20230227441A1 (en) 2023-07-20
AU2021292061A1 (en) 2023-01-19
WO2021257418A1 (en) 2021-12-23
CN116056697A (zh) 2023-05-02
EP4167994A1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
MX2022015581A (es) 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8.
MX2022015580A (es) 5-oxopirrolidin-3-carboxamidas como inhibidores de nav1.8.
MX2022015579A (es) 2-oxo-oxazolidin-5-carboxamidas como inhibidores de nav1.8.
ZA202102628B (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
CR20230519A (es) Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8
MX2021010625A (es) Derivado de pirazina y aplicacion del mismo en la inhibicion de shp2.
CR20230310A (es) Inhibidores de prmt5
MX2022015857A (es) Compuestos de dihidroquinolin sulfonamida de heteroalquilo.
CR20220584A (es) Inhibidores de kras tricíclicos fusionados
MX2022010011A (es) Inhibidores de prmt5 novedosos.
MX2022000244A (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas.
BR112023023186A2 (pt) 3-oxopiperazina carboxamidas de arila e 3-oxopiperazina carboxamidas de heteroarla como inibidores de nav1.8
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2021010870A (es) Bloqueadores de canales ionicos cargados y metodos de uso.
MX2021010869A (es) Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX2021002878A (es) Inhibidores de cd73 y usos farmaceuticos de los mismos.
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
MX2022011194A (es) Bloqueadores de canales ionicos cargados y metodos de uso.
MX2022005490A (es) Metodos para el tratamiento de trastornos depresivos.
MY148565A (en) Agent for therapy and/or improvement of disseminated intravascular coagulation
MX2023007150A (es) Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
MX2022013482A (es) Compuestos utiles para inhibir la quinasa ret.
MX2022012404A (es) Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas.
WO2019066548A3 (ko) 심부전의 예방 또는 치료용 약학적 조성물